Glatiramer acetate therapy for multiple sclerosis: A review

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 6, 2006, Pages 1019-1029

  Perumal, Jai ^a   Filippi, Massimo ^b   Ford, Corey ^c   Johnson, Kenneth ^d   Lisak, Robert ^a   Metz, Luanne ^e   Tselis, Alexandros ^a   Tullman, Mark ^f   Khan, Omar ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f NONE   (United States)

Author keywords

Glatiramer acetate; Immunomodulation therapy; Multiple sclerosis; Neuroprotection

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; ESTRIOL; GADOLINIUM; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINOCYCLINE; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; ANXIETY; AUTOIMMUNE DISEASE; AXONAL INJURY; BLOOD TOXICITY; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CHEST TIGHTNESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTRAST ENHANCEMENT; DEGENERATIVE DISEASE; DEPRESSION; DISEASE EXACERBATION; DRUG APPROVAL; DRUG CHOICE; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG MEGADOSE; DRUG MILK LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENCEPHALOMYELITIS; EVIDENCE BASED MEDICINE; FATIGUE; FLU LIKE SYNDROME; FLUSHING; HEART PALPITATION; HELPER CELL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INJECTION PAIN; INJECTION SITE ERYTHEMA; INJECTION SITE NECROSIS; INJECTION SITE REACTION; INJECTION SITE SWELLING; KIDNEY DISEASE; LIPODYSTROPHY; LIVER TOXICITY; LONG TERM CARE; LYMPHOCYTOPOIESIS; MATERNAL TREATMENT; MONOTHERAPY; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREGNANCY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SIDE EFFECT; SPASTICITY; SYSTEMIC DISEASE;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEURODEGENERATIVE DISEASES; PEPTIDES; TH2 CELLS; TREATMENT OUTCOME;

EID: 33845500556     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.6.1019     Document Type: Review

References (96)

1. KURTZKE JF: MS epidemiology world wide. One view of current status. Acta Neurol. Scand. (1995) 161:23-33.
2. INMAN R: Disability indices, the economic costs of illness, and social insurance: the case of multiple sclerosis. Acta Neurol. Scand. (1984) 70:46-55.
3. SOSPEDRA M, MARTIN R: Immunology of multiple sclerosis. Ann. Rev. Immunol. (2005) 23:683-747.
4. HAFLER DA, WEINER HL: T cells in multiple sclerosis and inflammatory central nervous system diseases. Immunol. Rev. (1987) 100:308-332.
5. MCFARLAND HF, DHIB-JALBUT S: Multiple sclerosis: possible immunological mechanisms. Clin. Immunol. Immunopath. (1989) 50:S96-S105.
6. OLSSON T: Immunology of multiple sclerosis. Curr. Opin. Neurol. Neurosurg. (1992) 5:195-202.
7. MARTIN R, MCFARLAND HF, MCFARLIN DE: Immunological aspects of demyelinating diseases. Ann. Rev. Immunol. (1992) 10:153-187.
8. SOLDAN SS, JACOBSON S: Role of viruses in etiology and pathogenesis of multiple sclerosis. Adv. Virus Res. (2001) 56:513-551.
9. SOLDAN SS, BETTI R, SALEM N et al.: Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat. Med. (1997) 3:1394-1397.
10. KARPAS A, KAMPF U, SIDEN A et al.: Lack of evidence for involvement of known human retroviruses in multiple sclerosis. Nature (1986) 322:177-178.
11. LUCHINETTI C, BRUCK W, PARISI J et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. (2000) 47:707-717.
12. WEINSHENKER BG, BASS B, RICE GP et al.: The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain (1989) 112:133-146.
13. ROVARIS M, GAMBINI A, GALLO A et al.: Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology (2005) 65:1626-1630.
14. PRINEAS JW, RAINE CS: Electron microscopy and immunoperoxidase studies of early multiple sclerosis. Neurology (1976) 26:29-32.
15. PRINEAS JW: The neuropathology of multiple sclerosis. In: Handbook of clinical neurology. Koetsier JC (Ed.), Elsevier Science Publishers, Amsterdam, The Netherlands (1985) 47:213-257.
16. TRAPP BD, PETERSON J, RANSOHOFF RM et al.: Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. (1998) 338:278-285.
17. BITCH A, SCHUCHARDT J, BUNKOWSKI S et al.: Axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain (2000) 123:1174-1183.
18. BERGER JR, KORALNIK IJ: Progressive multifocal leukoencephalopathy and natalizumab: unforeseen consequences. N. Engl. J. Med. (2005) 353:414-416.
19. TEITELBAUM D, MESHORER A, HIRSHFELD T, ARNON R, SELA M: Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. (1971) 1:242-248.
20. WEBB C, TEITELBAUM D, ARNON R, SELA M: In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur. J. Immunol. (1973) 3:279-286.
21. KEITH AB, ARNON R, TEITELBAUM D, CASPARY EA, WISNIEWSKI HM: The effect of Cop-1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J. Neurol. Sci. (1979) 42:267-274.
22. TEITELBAUM D, WEBB C, BREE M, MERSHORER A, ARNON R, SELA M: Suppression by several synthwetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur. J. Immunol. (1973) 3:273-279.
23. LISAK RP, ZWEIMAN B, BLANCHARD N, BORKE LB: Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J. Neurol. Sci. (1983) 62:281-293.
24. ARNON R, TEITELBAUM D, SELA M: Suppression of experimental allergic encephalomyelitis by Cop-1-relevance to multiple sclerosis. Isr. J. Med. Sci. (1989) 25:686-689.
25. SRIRAM S, STEINER J: Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol. (2005) 58:939-945.
26. NEUHAS O, FARINA C, WEKERLE H et al.: Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology (2001) 56:702-708.
27. H2-biased response and crossreactivity with myelin basic protein in patients with MS. Multiple Sclerosis (2001) 7:209-219.
28. GRAN B, TRANQUILL LR, CHEN M et al.: Mechanisms of immunomodulation by glatiramer acetate. Neurology (2000) 55:1704-1714.
29. DUDA PW, KRIEGER JI, SCHMIED MC et al.: Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate. J. Immunol. (2000) 165:7300-7307.
30. H2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Natl. Acad. Sci. USA (2000) 97:11472-11477.
31. FROHMAN EM, RACKE MK, RAINE CS: Multiple sclerosis - the plaque and its pathogenesis. N. Engl. J. Med. (2006) 354:942-955.
32. H-1 lymphokine subype. Cell. Immunol. (1989) 124:132-143.
33. QIN Y, DUQUETTE P, ZHANG Y, TALBOT P, POOLE R, ANTEL J: Clonal expression and somatic hypermutation of V(H) genes of B cells from the cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. (1998) 102:1045-1050.
34. OWENS GP, RITCHIE AM, BURGOON MP, WILLIAMSON RA, CORBOY JR, GILDEN DH: Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J. Immunol. (2003) 171:2725-2733.
35. ZIEMSSEN T, KUMPFEL T, KLINKERT WEF, NEUHAS O, HOHLFELD R: Glatiramer acetate specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain (2002) 125:2381-2391.
36. KIPNIS J, YOLES E, PORAT Z et al.: T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl. Acad. Sci. USA (2000) 97:7446-7451.
37. +) T cells predominate in CD8 responses to glatiramer acetate. J. Neuroimmunol. (2006) 178:117-129.
38. +CD25 high T regulatory cells and their IL-10 production in multiple sclerosis. J. Neuroimmunol. (2003) 144:125-131.
39. YONG VW: Differential mechanisms of action of interferon beta and glatiramer acetate in MS. Neurology (2002) 59:802-808.
40. FARINA C, WEBER MS, MEINL E, WEKERLE H, HOHLFELD R: Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. (2005) 4:567-575.
41. KIM HJ, IFERGAN I, ANTEL JP et al.: Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patient with multiple sclerosis. J. Immunol. (2004) 172:7144-7153.
42. ABRAMSKY O, TEITELBAUM D, ARNON R: Effect of a synthetic polypaptide (COP1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis. Preliminary report. J. Neurol. Sci. (1977) 31:433-438.
43. BORENSTEIN MB, MLLER AI, TEITELBAUM D et al.: Multiple sclerosis: a trial of synthetic polypetide. Ann. Neurol. (1982) 11:317-319.
44. BORENSTEIN MB, MILLER AI, SLAGLE S et al.: A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med. (1987) 317:408-414.
45. KURTZKE JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 33:1444-1452.
46. BORENSTEIN MB, MILLER A, SLAGLE S et al.: A placebo controlled, double-blind, randomized, two-center pilot trial of COP 1 in chronic progressive multiple sclerosis. Neurology (1991) 41:533-539.
47. JOHNSON KP, BROOKS BR, COHEN JA et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial. Neurology (1995) 45:1268-1276.
48. COHEN JA, GROSSMAN R, UDUPA J et al.: Assessment of the efficacy of copolymer-1 in the treatment of relapsing-remitting multiple sclerosis by quantitative MRI. Neurology (1995) 45(Suppl. 4):A418.
49. JOHNSON KP, BROOKS BR, COHEN JA et al.: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology (1998) 50:710-70832.
50. JOHNSON KP, BROOKS BR, FORD CC et al.: Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis (2000) 6:255-266.
51. JOHNSON KP, BROOKS BR, FORD CC et al.: Results of the long-term (8 year) prospective, open label trial of glatiramer acetate for relapsing multiple sclerosis. Neurolgy (2002) 58:A458.
52. FORD CC, JOHNSON KP, LISAK RP, PANITCH HS, SHIFRONI G, WOLINSKY JS; the COPAXONE STUDY GROUP: A prospective open-label study of glatiramer acetate: over a decade of continuos use in multiple sclerosis patients. Multiple Sclerosis (2006) 12:309-320.
53. CONCATO J, SHAH N, HOROWITZ RI: Randomized controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. (2000) 342:1887-1892.
54. BENSON K, ARTHUR HJ: A comparison of observational studies and randomized controlled trials. N. Engl. J. Med. (2000) 342: 1878-1886.
55. FILIPPI M, WOLINSKY JS, COMI G; THE CORAL STUDY GROUP: Effect of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, double-blind, randomized, placebo-controlled study. Lancet Neurol. (2006) 5:213-220.
56. WOLINSKY JS, PARDO L, STARK Y; PROMiSE STUDY GROUP: Effect of glatiramer acetate on primary progressive multiple sclerosis: Initial analysis of the completed PROMiSE trial. Neurology (2004) 62(Suppl. 5):A155.
57. FILIPPI M, GROSSMAN RI: MRI techniques to monitor MS evolution: the present and the future. Neurology (2002) 58:1147-1153.
58. POLMAN C, REINGOLD SC, EDAN G et al.: Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald criteria. Ann. Neurol. (2005) 58:840-846.
59. COMI G, FILIPPI M, WOLINSKY JS et al.: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing-remitting multiple sclerosis. Ann. Neurol. (2001) 49:290-297.
60. FILIPPI M, ROVARIS M, ROCCA M et al.: Glatiramer acetate reduces the proportion of new MS lesions evolving into 'black holes'. Neurology (2001) 57:731-733.
61. VAN WAESBERGHE JH, KAMPHORST W, DE GROOT CJ et al.: Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann. Neurol. (1999) 46:747-754.
62. BITSCH A, KUHLMAN T, STADELMAN C et al.: A longitudinally MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann. Neurol. (2001) 49:793-796.
63. SIMON HJ, JACOBS LD, CAMPION MK et al.: A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology (1999) 53:139-148.
64. SORMANI MP, ROVARIS M, VALSASINA P, WOLINSKY JS, COMI G, FILIPI M: Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology (2004) 62:1432-1434.
65. ROVARIS M, COMI G, ROCCA MA et al.: Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain (2001) 125:1676-1695.
66. Physician Desk Reference. Thomson PDR, Montvale, New Jersey, USA (2005) Edn 59:3221.
67. ROULLET E, VERDIER-TAILLEFER MH, AMARENCO P et al.: Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. J. Neurol. Neurosurg. Psychiatr. (1993) 56:1062-1065.
68. BERNARDI S, GRASSO MG, BERTOLLINI R, ORZI F, FIESCHI C: The influence of pregnancy on relapses in multiple sclerosis: a cohort study. Acta Neurol. Scand. (1991) 84:403-406.
69. CONFAVEURX C, HUTCHISON M, HOURS MM, CORTINOVIS-TOURNIAIRE P, MOREAU T: Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis group. N. Engl. J. Med. (1998) 339:285-291.
70. CAON C, KHAN OA: Use of immunomodulating therapy (IMT) during pregnancy in patients with multiple sclerosis (MS). J. Neurol. (2001) 248(Suppl. 3):86.
71. COYLE PK, JOHNSON K, PARDO L, STARK Y: Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate. Neurology (2003) 60:A60.
72. CAON C: Pregnancy and multiple sclerosis. In: Multiple Sclerosis: etiology, diagnosis, and new treatment strategies. Olek M (Ed.), Humana Press, New Jersey, USA (2005):145-160.
73. CARTER AR, CHEN C, SCHWARTZ PM, SEGAL BA: Brain derived nerotrophic factor modulates cerebellar plasticity and synaptic ultrastructure. J. Neurol. Sci. (2002) 22:1316-1327.
74. STADELMANN C, KERSCHENSTEINER M, MISGELD T, BRUCK W, HOHFELD R, LASSMAN H: BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain (2002) 125:75-85.
75. AHARONI R, KAYHAN B, EILAM R, SELA M, ARNON R: Glatiramer acetate-specific T cells in the brain express 2/3 cytokines and brain derived neurotrophic factor in situ. Proc. Natl. Acad. Sci. USA (2003) 100:14157-14162.
76. AHARONI R, EILAM R, DOMEY H et al.: Immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental allergic encephalomyelitis mice. Proc. Natl. Acad. Sci. USA (2005) 102:19045-19050.
77. GILGUN-SHERKI Y, PANET H, HOLDENGRGBER V, MOSBERG-GALILI R, OFFEN D: Axonal damage is reduced following glatiramer acetate treatment in C57/ bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci. Res. (2003) 47:201-207.
78. AHARONI R, ARNON R, EILAM R: Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neurol. Sci. (2005) 25:8217-8228.
79. STEINMAN J, ZAMVIL SS: How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. (2006) 60:12-21.
80. CHEN M, VALENZUELA RM, DHIB-JALBUT S: Glatiramer acetate-reactive T cells produce brain derived neurotrophic factor. J. Neurol. Sci. (2003) 215:37-44.
81. AZOULAY D, VACHAPOVA V, SHIHMAN B, MILLER A, KARNI A: Lower brain derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J. Neuroimmunol. (2005) 167:215-218.
82. KIPNIS J, YOLES E, PORAT Z et al.: T cell immunity to Copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapies for optic neuropathies. Proc. Natl. Acad. Sci. USA (2000) 97:7446-7451.
83. BITSCH A, BRUHN H, VOUGIOKAS V et al.: Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. Am. J. Neuroradiol. (1999) 20:1619-1627.
84. DE STEFANO N, MATTHHEWS PM, FU L et al.: Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain (1998) 121:1469-1477.
85. KHAN OA, SHEN Y, CAON C et al.: Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Multiple Sclerosis (2005) 6:646-651.
86. KHAN O, SHEN Y, HU J et al.: Sustained effect of glatiramer acetate (GA) on cerebral axonal injury in relapsing-remitting MS: results after three years of serial brain magnetic resonance spectroscopy (MRS) examinatton. J. Neurol. (2005) 252(Suppl. 2):II/127-128.
87. NARAYANA S, CARAMANOS Z, ARNOLD D: The effect of glatiramer acetate on axonal integrity in multiple sclerosis. Multiple Sclerosis (2004) 10(Suppl. 2):S256.
88. COHEN J, ROVARIS M, GOODMAN A, FILIPPI M; the MRI-AC STUDY GROUP: Results of a randomized, double-blind, parallel-group study assessing safety and efficacy of 40 mg versus 20 mg of glatiramer acetate on MRL-measured disease activity in RRMS. Neurology (2006) 66:S61.
89. MILO R, PANITCH H: Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J. Neuroimmunol. (1995) 61:185-193.
90. LUBLIN F, BAIER M, CUTTER G et al.: Results of the extension of a trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate. Neurology (2002) 58:A85.
91. RAMTAHAL J, JACOB A, DAS K, BOGGILD M: Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosupprression in very active, relapsing-remitting multiple sclerosis. J. Neurol. (2006) 253:1160-1164.
92. VOLLMER T, PANITCH HS, FREEDMAN MS et al.: Short-term induction with mitoxantrone preceding treatment with glatiramer acetate offers early and pronounced effects on MRI-disease activity in patients with relapsing forms of multiple sclerosis. Multiple Sclerosis (2006) 12(Suppl. 1):S11-S12.
93. GIULIANI F, METZ LM, WILSON T, FAN Y, BAR-OR A, YONG W: Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. (2005) 158:213-221
94. METZ LM, ZHANG Y, YEUNG M et al.: Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. (2004) 55:756.
95. GOODMAN A, PANZARA M, ROSSMAN H, KHAN O; the GLANCE STUDY INVESTIGATORS: A double-blind, placebo-controlled, parallel-group safety study of natalizumab (Antegren) in combination with glatiramer acetate (Copaxone) in subjects with relapsing-remitting multiple sclerosis. Neurology (2005) 64(Suppl. 1):A277-A278.
96. SICOTTE NL, LIVA SM, KLUTCH R et al.: Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. (2002) 52:421-428.